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Sir,
Cutaneous T-cell lymphoma (CTCL) deﬁnes a group of
lymphoproliferative disorders that primarily affects the skin.
Mycosis fungoides (MF) is the most common clinical variant of
CTCL comprising almost 50% of all patients diagnosed with
primary T-cell lymphoma.1 The etiology and pathogenesis of the
disease remain poorly understood. Recent data suggest that
environmental factors such as bacteria rather than heredity
play an important role in the pathogenesis and disease
progression.2–4 Although angiogenesis generally plays a key role
in tumor growth and metastasis and is considered one of the
hallmarks of cancer,5 little is known about angiogenesis in CTCL.
However, recent data demonstrated that micro-vessel formation
and the density of micro-vessels in CTCL skin lesions correlate with
disease progression suggesting that angiogenesis plays a role in
the pathogenesis.6 Notably, malignant inﬂammation deﬁned
as a pro-tumorigenic inﬂammatory environment orchestrated by
the tumor cells plays a key role in disease progression (reviewed
in ref. 7). Accordingly, we hypothesized that malignant T cells
also orchestra angiogenesis in affected skin. In support, malig-
nant T cells spontaneously produce angiogenic factors such as
VEGF-A, VEGF-C and lymphotoxin-alpha8–11 and induce increased
vascularization and production of angiogenic factors in vivo.12
Recent observations indicate that IL-17 family cytokines stimulate
and modulate oncogenic angiogenesis.13 Interestingly, due to
abnormal activation of the JAK3/STAT3 signaling pathway,
malignant T cells spontaneously express IL-17F and a fraction of
MF patients display increased levels of IL-17A and/or IL-17F in
lesional skin at levels comparable to those found in skin lesions
from patients with psoriasis,14 a disease which is also associated
with increased angiogenesis.15 Since malignant MF T cells
constitutively express IL-17F and the expression in lesional skin
is associated with progressive disease,14 we hypothesized that
malignant T cells partly promote angiogenesis through the
expression of IL-17F in MF patients. Accordingly, we plated
endothelial cells (HUVEC) on growth factor depleted matrigel
in vitro with or without culture supernatant from malignant T cell
lines (MyLa2059 and PB2B cells both of which spontaneously
produce IL-17F14) to assay for IL-17F mediated induction of
endothelial sprouting and tube formation as described
elsewhere.11
As shown in Figure 1, supernatant from the malignant T cell line
MyLa2059 rapidly induced strong sprouting and tube formation
(Figure 1b versus Figure 1a). Importantly, an IL-17F neutralizing
antibody inhibited the endothelial response (Figure 1c versus
Figure 1b) whereas an anti-IL-17A antibody (as a control) did not
(Figure 1d versus Figure 1c) which is in agreement with the
observation that MyLa2059 did not express IL-17A.14 The effect of
Figure 1. Malignant T cells (MyLa2059) trigger IL-17F- mediated endothelial tube formation. Endothelial tube formation assays were
performed on growth factor reduced matrigel in 24-well plates. HUVEC cell sprouting when cultured with (a) M200 medium, (b) supernatant
(10% vol/vol) from a malignant T cell line (MyLa2059), (c) MyLa2059 supernatant+anti-IL-17F antibody, and (d) MyLa2059 supernatant+anti-
IL-17A antibody.
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IL-17F neutralization on the endothelial response was comparable
to VEGF-A neutralization (Supplementary Figures S1A–S1E).
Essentially similar responses were seen in a series of three
independent experiments with MyLa2059 supernatants (Figure 2a)
and in independent experiments using supernatants from another
IL-17F producing malignant T cell line (the PB2B cell line)
(Supplementary Figure S2, and data not shown). On average,
endothelial responses to culture supernatants from malignant
T cells were signiﬁcantly inhibited by about 30% by the anti-IL-17F
neutralizing antibody (Figure 2a, column 2 versus 4) whereas the
control antibody as anticipated had no effect alone or in
combination with anti-IL-17F antibody (Figure 2a) indicating that
IL-17F produced by malignant T cells triggered endothelial
activation as evidenced by an increased branching. In accordance,
HUVEC cells expressed IL-17 receptor A (IL-17RA) and IL-17RC
(data not shown) and exogenous recombinant IL-17F induced
increased branching in endothelial cells conﬁrming that IL-17F
per se is able to activate endothelial cells (Figure 2b, column 4 and
5). Expectedly, recombinant IL-17A (Figure 2b, column 2 and 3)
and the well-characterized angiogenic factor VEGF-A (Figure 2b,
column 7) also induced enhanced endothelial cell branching and
tube formation. Neutralization of autocrine VEGF-induced signal-
ing did not affect STAT3 activation in malignant T cells
(Supplementary Figure S3). We have previously shown that STAT3
signaling pathway drives malignant IL-17F expression.14 Together,
our ﬁnding indicates that therapeutic inhibition of classic
angiogenic pathways, like VEGF, will not affect IL-17F production
by malignant T cells. As mentioned above, the malignant T cells
in question did not produce IL-17A, but it is seems likely that
IL-17A producing malignant T cells may also contribute to the
induction of angiogenesis in CTCL patients. Interestingly, simulta-
neous expression of IL-17A and IL-17F by malignant T cells leads
to IL-17A/IL-17F heterodimer formation in malignant
supernatant14 and as shown in Figure 2b (column 6) IL-17A and
IL-17F induce an enhanced response when compared to either
cytokine alone. Some patients with CTCL display high levels of
IL-17A, others display high levels of IL-17F, while some display
high levels of both cytokines in their lesional skin.14 The average
expression of IL-17A and IL-17F was increased in advanced stages
of CTCL when compared to early stages, indicating that both IL-17
family cytokines may be involved in disease progression although
only the correlation between IL-17F and progressive disease
was statistically signiﬁcant.14 Thus, it is conceivable that it is the
total level of IL-17A/IL-17F (alone or in combination) that
determines the impetus of these cytokines on the
angiogenesis in MF.
Taken together, the present ﬁndings suggest that malignant
T cells orchestra angiogenesis and malignant inﬂammation in
tandem, which might play an important role during the
accelerating disease progression observed in advanced stages of
the disease.
In conclusion, the present study provides the ﬁrst evidence that
malignant T cells stimulate angiogenesis through release of IL-17F
suggesting that IL-17F might serve as a novel target for anti-
angiogenic therapy.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
The authors thank K. Kaltoft for providing the MyLa cell line. This work was supported
in part by research funding from the Danish Cancer Society, the Danish Psoriasis
Foundation, the Danish Research Councils, the Lundbeck Foundation, the Novo
Nordic Foundation, and the University of Copenhagen.
B Lauenborg1, IV Litvinov2, Y Zhou3, A Willerslev-Olsen1,
CM Bonefeld1, C Nastasi1, S Fredholm1, LM Lindahl4,
D Sasseville5, C Geisler1, MM Wasik6, T Krejsgaard1,
LMR Gjerdrum7, L Iversen4, N Odum1
and A Woetmann1
1Department of Immunology and Microbiology, University of
Copenhagen, Copenhagen, Denmark;
2Division of Dermatology, Ottawa Hospital Research Institute,
University of Ottawa, Ottawa,
ON, Canada;
3Department of Dermatology and Skin Science, University of British
Columbia, Vancouver,
BC, Canada;
4Department of Dermatology, Aarhus University Hospital,
Aarhus, Denmark;
5Division of Dermatology, McGill University Health Centre, Montréal,
QC, Canada;
6Department of Pathology and Laboratory Medicine, University of
Pennsylvania, Philadelphia, PA, USA and
Figure 2. IL-17F increases the number of branching points and tube formation. Pictures of cultures were taken and the number of branching
points counted representing the morphogenic activity of HUVEC cells following incubation with (a) malignant CTCL cell line (MyLa2059)
supernatant (sup.) either alone or supplemented with anti-IL-17A or anti-IL-17F antibodies, *Po0.05 (paired t-test), or (b) in the presence of
rhIL-17A, rhIL-17F, rhIL-17A+rhIL-17F or VEGF-A for 12 h. Bars represent mean values of three independent experiments. *Po0.05, **Po0.01,
***Po0.001 compared to control (paired t-test).
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